Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acarbose
Drug ID BADD_D00018
Description Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued).[L31668] This class of antidiabetic therapy is not widely used due to their relatively modest impact on A1c, their requirement for thrice-daily dosing, and the potential for significant gastrointestinal adverse effects.[L31668]
Indications and Usage For treatment and management of diabetes type II (used in combination therapy as a second or third line agent)
Marketing Status Prescription
ATC Code A10BF01
DrugBank ID DB00284
KEGG ID D00216
MeSH ID D020909
PubChem ID 444254
TTD Drug ID D0AD5C
NDC Product Code 0054-0141; 0054-0140; 23155-148; 42291-132; 50090-4115; 64380-759; 72789-133; 65897-2005; 64380-758; 0054-0142; 42513-0016; 63629-5697; 63629-5698; 64380-760; 23155-149; 65897-1005; 23155-147; 69543-121; 69543-120; 69543-122; 71052-656; 42291-130; 71335-1583; 50090-4952; 52972-0035; 43353-951; 72789-131; 58623-0022; 50090-5088; 50090-5829; 42291-131; 72789-132; 50090-4116
Synonyms Acarbose | Glumida | Glucobay | Glucor | Bay g 5421 | Prandase | Precose
Chemical Information
Molecular Formula C25H43NO18
CAS Registry Number 56180-94-0
SMILES CC1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)O)CO)CO)O)O)NC4C=C(C(C(C4O)O)O)CO
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.012415%
Abdominal pain07.01.05.002--
Chest discomfort02.02.02.009; 08.01.08.019; 22.02.08.0010.004966%Not Available
Constipation07.02.02.001--
Cough22.02.03.0010.009932%
Death08.04.01.001--
Dehydration14.05.05.0010.007449%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.0010.022348%
Dizziness02.01.02.004; 17.02.05.003; 24.06.02.0070.029797%
Dyspepsia07.01.02.001--
Dyspnoea02.01.03.002; 22.02.01.0040.004966%
Erythema23.03.06.001--Not Available
Flatulence07.01.04.0020.004966%
Gastrointestinal disorder07.11.01.0010.004966%Not Available
Gastrointestinal pain07.01.05.005--
Hepatic function abnormal09.01.02.001--Not Available
Hepatitis09.01.07.004--Not Available
Hepatitis fulminant09.01.07.007; 11.07.01.003--Not Available
Hepatocellular injury09.01.07.008--Not Available
Hypersensitivity10.01.03.003--
Hypoglycaemia05.06.03.001; 14.06.03.0010.009932%
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Intestinal obstruction07.13.01.002--Not Available
Intestinal perforation07.04.06.002--Not Available
Intussusception07.13.01.008--Not Available
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030--Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages